Biomarkers in multiple sclerosis: Role of antibodies

Disease Markers

Volumn 22, Issue 4, 2006, Pages 207-212

  Berger, Thomas ^a   Reindl, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AUTOANTIBODY; BIOLOGICAL MARKER; GANGLIOSIDE; HEAT SHOCK PROTEIN 60; LECTIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFILAMENT PROTEIN; PROTEASOME; PROTEOLIPID PROTEIN; TRANSALDOLASE;

CEREBROSPINAL FLUID ANALYSIS; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL;

EID: 33751075501     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/602103     Document Type: Conference Paper

References (51)

1. N. Achiron, J. Rio, A.L. Fernandez, M. Tintore, I. Duran, I. Galan and X. Montalban, Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis, Acta Neurol Scand 93 (1996), 99-103.
2. M. Adelmann, J. Wood, I. Benzel, P. Fiori, H. Lassmann, J. M. Matthieu, V. Gardinier, K. Dornmair and C. Linington, The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat, J Neuroimmunol 63 (1995), 17-27.
3. M.A. Agius, C.A. Kirvan, A.L. Schafe, E. Gudipati and S. Zhu, High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease, Acta Neurol Scand 100 (1999), 139-147.
4. J.J. Archelos, M.K. Storch and H.P. Hartung, The role of B cells and antibodies in multiple sclerosis, Ann Neurol 47 (2000), 694-706.
5. J.J. Archelos, J. Trotter, S. Previtali, B. Weissbrich, K.V. Toyka and H.P. Hartung, Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis, Ann Neurol 43 (1998), 15-24.
6. S. Baig, T. Olsson, J. Yu-Ping, B. Hojeberg, M. Cruz and H. Link, Multiple sclerosis: cells secreting antibodies against myelin- associated glycoprotein are present in cerebrospinal fluid, Scand J Immunol 33 (1991), 73-79.
7. K. Banki, E. Colombo, F. Sia, D. Halladay, D.H. Mattson, A.H. Tatum, P.T. Massa, P.E. Phillipps and A. Perl, Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis, J Exp Med 180 (1994), 1649-1663.
8. T. Berger, Multiple sclerosis, in: Antibodies as Diagnostic and Predictive Markers of Autoimmune Diseases, A.L. Notkins, A. Lernmark and D. Leslie, eds, Autoimmunity 37(4) (2004), 321-324.
9. T. Berger, P. Rubner, R. Egg, F. Schautzer, H. Ulmer, I. Mayringer, E. Dilitz, F. Deisenhammer and M. Reindl, Antimyelin antibodies as predictors for clinical definite multiple sclerosis in patients with a first demyelinating event, New Engl J Med 146 (2003), 181-197.
10. J.M. Bronstein, R.L. Lallone, R.S. Seitz, G.W. Ellison and L.W. Myers, A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic, Neurology 53 (1999), 154-161.
11. W. Brück, K. Neubert, T. Berger and J.R. Weber, Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination - possible markers for an antibody-mediated process, Multiple Sclerosis 7 (2001), 173-177.
12. A.H. Cross, J.L. Trotter and J.A. Lyons, B cells and antibodies in CNS demyelinating disease, J Neuroimmunol 112 (2001), 1-14.
13. M. Cruz, T. Olsson, J. Ernerudh, B. Hojeberg and H. Link, Immunoblot detection of oligoclonal antimyelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis, Neurology 37 (1987), 1515-1519.
14. R. Egg, M. Reindl, F. Deisenhammer, C. Linington and T. Berger, Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis, Multiple Sclerosis 7 (2001), 285-289.
15. R. Ehling, A. Lutterotti, J. Wanschitz, M. Khalil, C. Gneiss, F. Deisenhammer, M. Reindl and T. Berger, Increased frequencies of serum antibodies to neurofilament-light in patients with primary chronic progressive multiple sclerosis, Multiple Sclerosis 10 (2004), 601-606.
16. S. Gaertner, K.L. de Graa, B. Greve and R. Weissert, Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis, Neurology 63 (2004), 2381-2383.
17. C.P. Genain, B. Cannella, S.L. Hauser and C.S. Raine, Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nature Med 5 (1999), 170-175.
18. M. Hawa, H. Beyan and R.D.G. Leslie, Principles of Autoantibodies as Disease-specific Markers, in: Antibodies as Diagnostic and Predictive Markers of Autoimmune Diseases, A.L. Notkins, A. Lernmark and D. Leslie, eds, Autoimmunity 37(4) (2004), 253-256.
19. B. Hemmer, J.J. Archelos and H.P. Hartung, New concepts in the immunopathogenesis of multiple sclerosis, Nature Neurosci Rev 3 (2002), 291-301.
20. E.A. Kabat, M. Glusman and V. Knaub, Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods, Am J Med 4 (1948), 653-662.
21. N. Kerlero de Rosbo, R. Milo, M. B. Lees, D. Burger, C.C. Bernard and A. Ben-Nun, Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein, J Clin Invest 92 (1993), 2602-2608.
22. B. Kornek and H. Lassmann, Neuropathology of multiple sclerosis - new concepts, Brain Res Bull 61 (2003), 321-326.
23. V. Lampasona et al., Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects, Neurology 62 (2004), 2092-2094.
24. H. Lassmann, W. Brück and C. Lucchinetti, Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy, Trends Mol Med 7 (2001), 115-121.
25. H. Lassmann, M. Reindl, H. Rauschka, J. Berger, F. Aboul-Enein, T. Berger, A. Zurbriggen, A. Lutterotti, W. Brück, J.R. Weber, R. Ullrich, M. Schmidbauer, K. Jellinger and M. Vandervelde, A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions, Brain 126 (2003), 1-11.
26. P.V. Lehmann, T. Forsthuber, A. Miller and E.E. Sercarz, Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen, Nature 358 (1992), 155-157.
27. E.T. Lim, T. Berger, M. Reindl, C.M. Dalton, K. Fernando, G. Keir, E.J. Thompson, D.H. Miller and G. Giovannoni, Antimyelin antibodies do not allow earlier diagnosis of multiple sclerosis, Multiple Sclerosis 11 (2005), 492-494.
28. C. Linington, M. Bradl, H. Lassmann, C. Brunner and K. Vass, Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein, Am J Pathol 130 (1988), 443-454.
29. C.F. Lucchinetti, W. Bruck, M. Rodriguez and H. Lassmann, Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis, Brain Pathol 6 (1996), 259-274.
30. C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez and H. Lassmann, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol 47 (2000), 707-717.
31. I. Mayo, J. Arribas, P. Villoslada, R. Alvarez Do Forno, S. Rodriguez-Vilarino, X. Montalban, M.R. de Sagarra and J.G. Castano, The proteasome is a major autoantigen in multiple sclerosis, Brain 125 (2002), 2658-2667.
32. J.R. Moller, D. Johnson, R.O. Brady, W.W. Tourtelotte and R.H. Quarles, Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients, J Neuroimmunol 22 (1989), 55-61.
33. J.H. Noseworthy, C. Lucchinetti, M. Rodriguez and B.G. Weinshenker, Multiple Sclerosis, New Engl J Med 343 (2000), 938-952.
34. J.E. Olsson and H. Link, Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remission, Arch Neurol 28 (1973), 392-399.
35. T. Olsson, S. Baig, B. Hojeberg and H. Link, Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis, Ann Neurol 27 (1990), 132-136.
36. S. Prabhakar, E. Kurien, R.S. Gupta et al., Heat shock protein immunoreactivity in the CSF: correlation with oligoclonal banding and demyelinating disease, Neurology 44 (1994), 1644-1648.
37. A.T. Reder and J.J. Oger, Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis (Editorial), Neurology 62 (2004), 1922-1923.
38. M. Reindl, C. Linington, U. Brehm, R. Egg, E. Dilitz, F. Deisenhammer, W. Poewe and T. Berger, Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological disease: a comparative study, Brain 122 (1999), 2047-2056.
39. B.T. Sadatipour, J.M. Greer and M.P. Pender, Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis, Ann Neurol 44 (1998), 980-983.
40. E. Silber, Y.K. Semra, N.A. Gregson and M.K. Sharief, Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit, Neurology 58 (2002), 1372-1381.
41. M. Sospedra and R. Martin, Immunology of Multiple Sclerosis, Ann Rev Immunol 23 (2005), 683-747.
42. M.K. Storch, A. Stefferl, U. Brehm, R. Weissert, E. Wallstrom, M. Kerschensteiner, T. Olsson, C. Linington and H. Lassmann, Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology, Brain Pathol 8 (1998), 681-694.
43. M.K. Storch, S. Piddlesden, M. Haltia, M. Ivanainen, P. Morgan and H. Lassmann, Multiple sclerosis: in situ evidence for antibody- and complement mediated demyelination, Ann Neurol 43 (1998), 465-471.
44. J.B. Sun, T. Olsson, W.Z. Wang, B.G. Xiao, S. Fredrikson, H.P. Ekre and H. Link, Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls, Eur J Immunol 21 (1991), 1461-1468.
45. J. Sun, H. Link, T. Olsson, B.G. Xiao, G. Andersson, H.P. Ekre, C. Linington and P. Diener, T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis, J Immunol 146 (1991), 1490-1493.
46. L.M. Villar, J. Masjuan, P. Gonzalez-Porque et al., Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS, Neurology 59 (2002), 555-559.
47. L.M. Villar, J. Masjuan, P. Gonzalez-Porque, J. Plaza, M.C. Sadaba, E. Roldan, A. Bootello and J.C. Alvarez-Cermeno, Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis, Ann Neurol 53 (2003), 222-226.
48. M.J. Walsh and J.M. Murray, Dual implication of 2′,3′-cyclic nucleotide 3 phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis, J Clin Invest 101 (1998), 1923-1931.
49. K.G. Warren and I. Catz, Relative frequency of autoantibodies to myelin basic protein and proteolipidprotein in optic neuritis and multiple sclerosis cerebrospinal fluid, J Neurol Sci 121 (1994), 66-73.
50. B.G. Xiao, C. Linington and H. Link, Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls, J Neuroimmunol 31 (1991), 91-96.
51. J.P. Zanetta, C. Tranchant, S. Kuchler-Bopp et al., Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: a sensitive and specific test in the diagnosis of multiple sclerosis, J Neuroimmunol 52 (1994), 175-182.